How is refractory or relapsing ANCA-associated vasculitis treated?

Updated: Dec 10, 2018
  • Author: Nadia Jennifer Chiara Luca, MD; Chief Editor: Lawrence K Jung, MD  more...
  • Print

The RAVE trial, [38] a randomized, controlled, double-blinded study of cyclophosphamide versus rituximab in ANCA vasculitis, included a planned subgroup analysis of patients with refractory or relapsing disease. The findings demonstrated that rituximab was particularly effective in this population. Several other small series also report the effectiveness of rituximab in patients with refractory or relapsing disease. Other options for refractory or relapsing disease include IVIG, mycophenolate mofetil, infliximab, 15-deoxyspergualin, and antithymocyte globulin. [35]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!